Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Virology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Pathogenesis and Immunity

Role for the Paramyxovirus Genomic Promoter in Limiting Host Cell Antiviral Responses and Cell Killing

Mary J. Manuse, Griffith D. Parks
Mary J. Manuse
Department of Microbiology and Immunology, Wake Forest University, School of Medicine, Winston-Salem, North Carolina 27157-1064
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Griffith D. Parks
Department of Microbiology and Immunology, Wake Forest University, School of Medicine, Winston-Salem, North Carolina 27157-1064
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: gparks@wfubmc.edu
DOI: 10.1128/JVI.01055-09
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • FIG. 1.
    • Open in new tab
    • Download powerpoint
    FIG. 1.

    Schematic diagram of SV5 genomic promoter and viruses used in this study. (A) Genomic promoter. The 3′-to-5′ sequence of the 90-base SV5 genomic promoter is shown, with the positions of nucleotides that differ between WT SV5 (top) and the WF-PIV variant of SV5 (bottom). The three hexamers that compose PrE-I and PrE-II are denoted by underlining, and the start site for transcription of the NP gene is shown by an arrow. (B) The genome structure of SV5 is shown, with the addition of the GFP gene between HN and L, as described previously (16). The sequences at positions 5 and 14 in the PrE-I region that differ between WT SV5-GFP and the Le-(U5C, A14G) mutant are indicated. le, leader; tr, trailer.

  • FIG. 2.
    • Open in new tab
    • Download powerpoint
    FIG. 2.

    The Le-(U5C, A14G) mutant overexpresses viral protein compared to WT SV5. (A) Microscopy. A549 cells were mock infected or infected at an MOI of 10 with SV5-GFP or the Le-(U5C, A14G) mutant. Cells were examined by microscopy at 24 h p.i. (B) Rate of viral protein synthesis. A549 cells were mock infected (lane M) or infected at an MOI of 10 with SV5-GFP or the Le-(U5C, A14G) mutant. At the indicated times p.i., cells were radiolabeled for 20 min with Tran[35S]-label. Cells were lysed, and equal amounts of protein were immunoprecipitated with antibodies to the indicated proteins before analysis by SDS-polyacrylamide gel electrophoresis and autoradiography. Numbers beneath the autoradiograms indicate the expression levels relative to those for WT-infected cells at 16 h p.i. (C and D) Virus growth kinetics. A549 cells were infected at an MOI of 10 (C) or 0.05 (D), and virus in the media at the indicated times p.i. was quantitated by plaque assay. Data are representative of three independent experiments.

  • FIG. 3.
    • Open in new tab
    • Download powerpoint
    FIG. 3.

    Accumulation of Le-(U5C, A14G) mutant mRNA and genomic RNA. A549 cells were mock infected (lane M) or infected at an MOI of 10 with SV5-GFP or the Le-(U5C, A14G) mutant. At the indicated times p.i., RNA was harvested as described in Materials and Methods and analyzed by an RPA using 32P-labeled riboprobes specific for M mRNA or the leader-NP junction for genomic RNA. − and + indicate control samples where riboprobe alone was incubated without or with nuclease, respectively. The − lanes represent 1/50 of the input probe for each sample. The number for each lane indicates the change in signal (n-fold) relative to the level at 18 h p.i., with the level for SV5-GFP set at 1.0.

  • FIG. 4.
    • Open in new tab
    • Download powerpoint
    FIG. 4.

    Induction of proinflammatory cytokines and IFN by the Le-(U5C, A14G) mutant but not by WT SV5. (A, B, and C) Induction of cytokines. A549 cells were mock infected or infected at an MOI of 10 with SV5-GFP or the Le-(U5C, A14G) mutant, and at the indicated times p.i., levels of secreted IL-6 (A and B) or IFN-β (C) were determined by ELISA. Results are the expressed as mean values from triplicate samples, with error bars representing standard deviations, and are normalized to the level for 106 cells. *, P value of <0.005 compared to corresponding samples from control cells. For panel B, the Le-(U5C, A14G) mutant virus was treated with (+) or without (−) UV light prior to infection. (D) IRF-3 nuclear translocation. A549 cells were infected at an MOI of 10 with the indicated viruses. At 24 h p.i., cells were stained for IRF-3 using a monoclonal antibody and for the nucleus using DAPI (4′,6-diamidino-2-phenylindole).

  • FIG. 5.
    • Open in new tab
    • Download powerpoint
    FIG. 5.

    The Le-(U5C, A14G) mutant (Mut) encodes a functional V protein. (A) Time course of V protein expression. A549 cells were infected at a high MOI, and at the indicated times p.i., cell lysates were analyzed by Western blotting for levels of V protein and cellular actin. (B) Cells infected with the indicated viruses were labeled at 24 h p.i. for 30 min with [35S]cysteine before immunoprecipitation with anti-V protein antibody. (C) STAT1 levels. A549 cells were infected at an MOI of 10 with the indicated viruses. Cell lysates were prepared at 8 h p.i., and levels of STAT1 and actin were determined by Western blotting.

  • FIG. 6.
    • Open in new tab
    • Download powerpoint
    FIG. 6.

    Role of RIG-I in cytokine induction by the Le-(U5C, A14G) mutant (Mut). (A) RIG-I knockdown. A549 cells were left untreated (lane 1) or transfected with control siRNA (lane 2) or siRNA targeting RIG-I (lane 3). Forty-eight hours posttransfection, levels of RIG-I and actin were assayed by Western blotting. (B and C) Cytokine secretion. A549 cells were transfected with control siRNA or siRNA specific for RIG-I. At 48 h posttransfection, cells were mock infected or infected at an MOI of 10 with SV5-GFP or the Le-(U5C, A14G) mutant, and levels of secreted IL-6 (B) or IFN-β (C) were measured by ELISA at 24 h p.i. Results are expressed as mean values from triplicate samples, with error bars representing standard deviations, and are normalized to the level for 106 cells. *, P value of <0.005 compared to corresponding samples from control cells.

  • FIG. 7.
    • Open in new tab
    • Download powerpoint
    FIG. 7.

    Role of dsRNA in cytokine induction by the Le-(U5C, A14G) mutant (Mut). (A) A549 cells expressing reovirus sigma3 protein. Control A549 cells or cells that stably express the reovirus sigma3 protein were analyzed by Western blotting for levels of sigma3. (B and C) Cytokine secretion. Control or sigma3-expressing A549 cells were mock infected or infected at an MOI of 10 with the Le-(U5C, A14G) mutant, and levels of secreted IL-6 were measured by ELISA at the indicated times p.i. For panel C, IFN-β levels were determined at 24 h p.i. Results are expressed as mean values from triplicate samples, with error bars representing standard deviations. * and #, P values of <0.005 and <0.05, respectively, compared to corresponding samples from control cells. (D) Viral M mRNA levels in sigma3-expressing cells. Control or sigma3-expressing A549 cells were mock infected or infected at an MOI of 10 with the indicated viruses. RNA harvested at 48 h p.i. was analyzed by an RPA with a probe specific for M mRNA. − and + indicate control samples where riboprobe alone was incubated without or with nuclease, respectively. The − lane represents 1/50 of the input probe for each sample. M, mock; SV5, SV5-GFP; le, Le-(U5C, A14G) mutant.

  • FIG. 8.
    • Open in new tab
    • Download powerpoint
    FIG. 8.

    Cytopathic effect induced by the Le-(U5C, A14G) mutant (Mut) but not WT SV5-GFP. (A) A549 cells were infected at an MOI of 10 with SV5-GFP or the Le-(U5C, A14G) mutant, and microscopy pictures were taken at 48 and 72 h p.i. (B) Cell viability. A549 or HeLa cells were mock infected or infected with the indicated viruses at an MOI of 10. Cell viability was determined at 48, 72, and 96 h p.i. using a cell viability assay. Data are from quadruplicate samples and are expressed as percentages of the values obtained with mock-infected cells. Error bars represent the standard deviations.

  • FIG. 9.
    • Open in new tab
    • Download powerpoint
    FIG. 9.

    The Le-(U5C, A14G) mutant (Mut) induces cytopathic effects that correlate with increased levels of F protein and cell-cell fusion. (A) Cell viability. Control or sigma3-expressing A549 cells were mock infected or infected with the indicated viruses at an MOI of 10. Cell viability was determined at 48, 72, and 96 h p.i. using a cell viability assay as described in the legend for Fig. 8. Error bars represent the standard deviations. (B) Microscopy pictures. A549 or BHK cells were mock infected or infected with the indicated viruses at an MOI of 10. Microscopy pictures were taken at 48 h p.i. Arrows indicate syncytium pockets. (C) Rate of F protein expression and cleavage. A549 cells that were mock infected or infected with the indicated viruses were pulse-labeled for 20 min with Tran[35S]-label. Cells were either lysed immediately (pulse lanes, P) or lysed after incubation for 3 h in nonradioactive media (chase lanes, C), immunoprecipitated with anti-F antiserum, and analyzed by SDS-polyacrylamide gel electrophoresis and autoradiography.

PreviousNext
Back to top
Download PDF
Citation Tools
Role for the Paramyxovirus Genomic Promoter in Limiting Host Cell Antiviral Responses and Cell Killing
Mary J. Manuse, Griffith D. Parks
Journal of Virology Aug 2009, 83 (18) 9057-9067; DOI: 10.1128/JVI.01055-09

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Virology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Role for the Paramyxovirus Genomic Promoter in Limiting Host Cell Antiviral Responses and Cell Killing
(Your Name) has forwarded a page to you from Journal of Virology
(Your Name) thought you would be interested in this article in Journal of Virology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Role for the Paramyxovirus Genomic Promoter in Limiting Host Cell Antiviral Responses and Cell Killing
Mary J. Manuse, Griffith D. Parks
Journal of Virology Aug 2009, 83 (18) 9057-9067; DOI: 10.1128/JVI.01055-09
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Genome, Viral
Immunity, Innate
parainfluenza virus 5
Promoter Regions, Genetic

Related Articles

Cited By...

About

  • About JVI
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #Jvirology

@ASMicrobiology

       

 

JVI in collaboration with

American Society for Virology

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0022-538X; Online ISSN: 1098-5514